Characterization of Prognostic Factors and Efficacy in a Phase-II Study with Docetaxel and Estramustine for Advanced Hormone Refractory Prostate Cancer-Reference-Cited by-同舟云学术

Characterization of Prognostic Factors and Efficacy in a Phase-II Study with Docetaxel and Estramustine for Advanced Hormone Refractory Prostate Cancer

Published:2005 Issue:11 Volume:28 Page:573-578
ISSN:2296-5270
Container-title:Oncology Research and Treatment
language:en
Short-container-title:Oncol Res Treat

Author:

Nelius Thomas,Reiher Frank,Lindenmeir Tobias,Klatte Tobias,Rau Olrik,Burandt Jens,Filleur Stephanie,Allhoff Ernst Peter

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,Hematology

Reference32 articles.

1. A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

2. Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer

3. Cancer Statistics, 2004

4. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

5. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2015-05-26

2. Liver Metastases from Prostate Cancer;Noncolorectal, Nonneuroendocrine Liver Metastases;2014-10-29

3. PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials;Tumor Biology;2014-09-07

4. Major Response to Cyclophosphamide and Prednisone in Recurrent Castration-Resistant Prostate Cancer;Journal of the National Comprehensive Cancer Network;2013-08

5. Docetaxel;Drugs;2012-07